BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Business

  Vertex Pharmaceuticals (MA) Announces A Signed Letter Of Intent To Enable Public Reimbursement Of KALYDECO® (Ivacaftor) In Canada For Eligible People With Cystic Fibrosis

  June 17, 2014

   · 

  1 min read
• Policy

  Harrisvaccines Becomes First In The Nation To Receive United States Department Of Agriculture (USDA) Conditional License For PEDv Vaccine

  June 17, 2014

   · 

  2 min read
• Business

  Enterome And Mayo Clinic Enter Collaboration To Develop And Commercialize Microbiome-Based Diagnostic Tools For Nutritional Interventions

  June 17, 2014

   · 

  3 min read
• BioMidwest

  MicroBiome Therapeutics LLC Cites Proof Of Concept Study Showing Metformin Improves Glycemic Control In Diabetes By Shifting The GI Microbiome

  June 17, 2014

   · 

  5 min read
• BioMidwest

  Illinois CyberKnife Launches Liver Cancer Study

  June 17, 2014

   · 

  2 min read
• Pharm Country

  Icahn School Of Medicine At Mount Sinai And Champions Oncology, Inc. Initiate Study Evaluating Tumorgrafts’ Ability To Predict Treatment Benefit In Patients With Triple-Negative Breast Cancer

  June 17, 2014

   · 

  5 min read
• Drug Development

  Mirati Therapeutics Receives Orphan Drug Designation From U.S. FDA For Mocetinostat In Myelodysplastic Syndrome

  June 17, 2014

   · 

  4 min read
• Biotech Beach

  Avidity NanoMedicines Announces Issuance Of Two Landmark Patents For Antibody-Sirna Complex (ARC™) Technology

  June 17, 2014

   · 

  1 min read
• FDA

  Osprey Medical Inc. Receives U.S. FDA Clearance For The AVERT™ System

  June 17, 2014

   · 

  3 min read
• Drug Development

  Eli Lilly and Company’s Once-Weekly Dulaglutide Shows Similar Reductions In Average Blood Glucose Levels As Once-Daily Liraglutide In Head-to-Head Trial

  June 17, 2014

   · 

  5 min read